A Simple Method for Analyzing Factor IX Activation in the Patients with Hemophilia B Variants

Summary

A simple method for analyzing the activation mechanism of FIX in patients with hemophilia B variants is described. The procedure consists of rapid partial purification of FIX by BaCl₂ adsorption-elution from only 3 ml of plasma, incubation with FXIa/Ca²⁺, SDS-PAGE, western blotting and subsequent autoradiography using monoclonal anti-FIX antibody. Abnormal FIX from the plasma of 7 unrelated patients with hemophilia B^R, B⁺ or BM was investigated. A time course study showed that FIX in the patient with hemophilia BM (Nagoya I), BM (Nagoya II) and B Kawachinagano seemed not to be cleaved by FXIa, FIX in the patient with hemophilia B Kashihara was partially cleaved, FIX in the patient with hemophilia BM (Takatsuki) showed delayed cleavage, and that FIX in the patient with hemophilia BM (Niigata) and BM (Kiryu) was cleaved completely at a rate similar to normal FIX. These findings were identical to those previously observed for the respective factors in a purified system. The procedure used here is useful for screening for a defective activation mechanism of abnormal FIX.

Key words

Hemophilia B - Factor IX - Activation of Factor IX - Monoclonal Antibody

• References

• 1 Roberts HR, Grizzle JE, McLester WD, Penick GD. Genetic variants of hemophilia B. Detection by means of a specific PTC inhibitor. J Clin Invest 1968; 47: 360-365
• 2 Brown PE, Hougie C, Roberts HR. The genetic heterogeneity of hemophilia B. N Engl J Med 1970; 283: 61-64
• 3 Kasper CK, Osterud B, Minami JY, Shonick W, Rapaport SI. Hemophilia B: Characterization of genetic variants and detection of carriers. Blood 1977; 50: 351-366
• 4 Fujimura Y, Takase T, Sakai T, Shima M, Fukui H. Immunological studies on factor IX antigen in patients with hemophilia B variant. Acta Haematol Jpn 1982; 45: 952-961 (Japanese)
• 5 DiScipio RG, Kurachi K, Davie EW. Activation of human Factor IX (Christmas factor). J Clin Invest 1978; 61: 1528-1538
• 6 Bajaj SP, Rapaport SI, Russell WA. Redetermination of the rate-limiting step in the activation of factor IX by factor XIa and by factor Vlla/tissue factor. Explanation for different electrophoretic radioactivity profiles obtained on activation of ³H- and ¹²T-labeled factor IX. Biochemistry 1983; 22: 4047-4053
• 7 Briet EM, Griffith MJ, Braunstein KM, Roberts HR. Determination of the relative activities of two factor IX variants - factor IX_{Chapel Hill} and factor IX_Ala5ama - in a purified factor X activating system. Blood 1981; 58 (suppl) 212a (Abstr.758)
• 8 Mertens K, Cupers R, van der Linden IK, Bertina RM. The functional defect of factor IX_Eindhoven, a genetic variant of factor IX. Thromb Haemostas 1983; 50: 249 (Abstr 783)
• 9 Usharani P, Warn-Cramer BJ, Kasper CK, Bajaj SP. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site. J Clin Invest 1985; 75: 76-83
• 10 Yoshioka A, Ohkubo Y, Nishinura T, Tanaka I, Fukui H, Ogata K, Kamiya T, Takahashi H. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca²⁺ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata. Thromb Res 1986; 42: 595-604
• 11 Davis LM, McGraw RA, Graham JB, Roberts HR, Stafford DW. Identification of the genetic defect in factor IX Alabama. DNA sequence analysis reveals a Gly substitution for Asp⁴⁷ . Blood 1984; 61: 262a
• 12 Bertina RM, van der Linden IK. Factor IX Deventer - Evidence for the heterogeneity of hemophilia Bm. Thromb Haemostas 1982; 47: 136-140
• 13 Fukui H, Fujimura Y, Shima M, Sakai T, Mikami S, Yoshioka A. Partial proteolytic susceptibility to contact activation in hemophilia B⁺ with slightly prolonged bovine brain prothrombin time. J Nara Med Ass 1981; 32: 526-536
• 14 Chung K-S, Marder DA, Goldsmith JC, Kingdon HS, Roberts HR. Purification and characterization of an abnormal factor IX (Christmas Factor) molecule. Factor IX Chapel Hill. J Clin Invest 1978; 62: 1078-1085
• 15 Braunstein KM, Noyes CM, Griffith MJ, Lundblad RL, Roberts HR. Characterization of the defect in activation of Factor IX Chapel Hill by human Factor XIa. J Clin Invest 1981; 68: 1420-1426
• 16 Noyes CM, Griffith MJ, Roberts HR, Lundblad RL. Identification of the molecule defect in factor IX Chapel Hill: Substitution of histidine for arginine at position 145. Proc Natl Acad Sci USA 1983; 80: 4200-4202
• 17 Bertina RM, van der Linden IK. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high moleeulai weight. J Lab Clin Med 1982; 100: 695-704
• 18 Diuguid DL, Rabiet MJ, Furie BC, Liebman HA, Furie B. Moleiular basis of hemophilia B: A defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor. Proc Natl Acad Sci USA 1986; 83: 5803-5807
• 19 Bentley AK, Rees DJG, Rizza C, Brownlee GG. Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4. Cell 1986; 45: 343-348
• 20 Nishimura T, Ohkubo Y, Nishino M, Sakai T, Sawai J, Tanaka I, Takamiya O, Yoshioka A. Preparation of factor IX deficient plasma by immunoadsorption using monoclonal antibody (3A6) to factor IX and its application. Jap J Clin Path 1986; 34: 469-474 (Japanese)
• 21 Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and jaundice. Am J Med Sci 1935; 190: 501-511
• 22 Oslerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
• 23 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
• 24 Towbin H, Stahelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 1979; 76: 4350-4354
• 25 Burnette WN. Western blotting: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Bioehem 1981; 112: 195-203
• 26 Yoshioka A, Giddings JC, Thomas JE, Fujimura Y, Bloom AL. Immunoassays of factor IX antigen using monoclonal antibodies. Br J Haematol 1985; 59: 265-275